TELA Bio, Inc. (NASDAQ:TELA - Get Free Report) saw a large decline in short interest in the month of February. As of February 28th, there was short interest totalling 467,800 shares, a decline of 15.9% from the February 13th total of 556,500 shares. Based on an average daily trading volume, of 171,100 shares, the short-interest ratio is currently 2.7 days. Currently, 1.3% of the company's shares are sold short.
Institutional Investors Weigh In On TELA Bio
Institutional investors have recently added to or reduced their stakes in the stock. GSA Capital Partners LLP lifted its position in TELA Bio by 398.8% in the 3rd quarter. GSA Capital Partners LLP now owns 112,205 shares of the company's stock valued at $284,000 after acquiring an additional 89,712 shares in the last quarter. Landscape Capital Management L.L.C. bought a new stake in TELA Bio in the 3rd quarter valued at $362,000. Stonepine Capital Management LLC lifted its position in TELA Bio by 77.4% in the 3rd quarter. Stonepine Capital Management LLC now owns 1,110,000 shares of the company's stock valued at $2,808,000 after acquiring an additional 484,355 shares in the last quarter. Archon Capital Management LLC bought a new stake in TELA Bio in the 4th quarter valued at $453,000. Finally, Renaissance Technologies LLC lifted its position in TELA Bio by 185.5% in the 4th quarter. Renaissance Technologies LLC now owns 425,140 shares of the company's stock valued at $1,284,000 after acquiring an additional 276,240 shares in the last quarter. 94.35% of the stock is owned by institutional investors.
TELA Bio Trading Up 0.4 %
Shares of TELA stock traded up $0.01 on Wednesday, hitting $2.36. The stock had a trading volume of 137,138 shares, compared to its average volume of 199,684. TELA Bio has a twelve month low of $2.18 and a twelve month high of $6.50. The firm has a market cap of $92.96 million, a P/E ratio of -1.40 and a beta of 1.10. The company has a current ratio of 2.62, a quick ratio of 1.81 and a debt-to-equity ratio of 14.22. The company has a fifty day moving average price of $2.60 and a two-hundred day moving average price of $2.71.
About TELA Bio
(
Get Free Report)
TELA Bio, Inc, a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs.
Further Reading
Before you consider TELA Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TELA Bio wasn't on the list.
While TELA Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
